Title
Anemia correction using Roxadustat among MHD patients: 50mg versus 100mg dosing schedules
Authors
Kazi Shahnoor Alam*, M. Masud Iqbal, Rokhsana Alam Ripa, K.U.M. Shamsun Naher & Md. Babrul Alam
Affiliation
Department of Nephrology, National Institute of Kidney Disease & Urology, Dhaka, Bangladesh; *Corresponding author
Kazi Shahnoor Alam - E-mail: kshahnoor@yahoo.com; Phone: +88 01711229151
M. Masud Iqbal - E-mail: masud_1232001@yahoo.com; Phone: +88 0171684930
Rokhsana Alam Ripa - E-mail: rokhsanaalamripa@gmail.com; Phone: +88 0139849876
Article Type
Research Article
Date
Received March 1, 2026; Revised March 31, 2026; Accepted March 31, 2026, Published March 31, 2026
Abstract
Anemia is a common complication in maintenance hemodialysis (MHD) patients. Hence, roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, was evaluated at two dosing schedules (50 mg versus 100 mg) in a randomized, open-label study of 65 patients. Both doses significantly increased hemoglobin and reduced red cell transfusion requirements over 12 weeks. The 100 mg dose produced a quicker and more pronounced response. Headaches were frequent but manageable and blood pressure remained stable. Roxadustat was well tolerated, supporting its role as a viable treatment option for anemia in dialysis patients.
Keywords
Roxadustat, kidney disease, renal anemia, maintenance hemodialysis (MHD)
Citation
Alam et al. Bioinformation 22(3): 1606-1610 (2026)
Edited by
Rashmi Laddha
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
